AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36631895 — intervention group
Group type: EXPERIMENTAL
Intervention: Light breakfast (14 g protein, 2218 kJ)
Number of subjects: 63
Study 36632042 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACYW-TT booster
Number of subjects: 401
Study 36632042 — intervention group
Group type: COMPARATOR
Intervention: MPSV4
Number of subjects: 401
Study 36632042 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACYW-TT
Number of subjects: 401
Study 36632042 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACYW-TT and MPSV4
Number of subjects: 401
Study 36632126 — intervention group
Group type: EXPERIMENTAL
Intervention: probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 43
Study 36632126 — intervention group
Group type: EXPERIMENTAL
Intervention: blinded pCLE reinterpretation
Number of subjects: 43
Study 36632126 — intervention group
Group type: EXPERIMENTAL
Intervention: pCLE
Number of subjects: 43
Study 36632180 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 35
Study 36632180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 36632603 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline attention
Number of subjects: 107
Study 36632603 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive control and working memory
Number of subjects: 107
Study 36632738 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax and rituximab (VenR) combination treatment
Number of subjects: 75
Study 36632758 — intervention group
Group type: EXPERIMENTAL
Intervention: MIP (metamizole, ibuprofen, paracetamol)
Number of subjects: 110
Study 36632758 — intervention group
Group type: COMPARATOR
Intervention: i.p. (ibuprofen and paracetamol)
Number of subjects: 110
Study 36632763 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 0
Study 36632831 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular tachycardia (VT) and ventricular fibrillation (VF) reported as adverse events, incidence rate 0.3 per 100 person-years.
Number of subjects: 13609
Study 36632831 — intervention group
Group type: EXPERIMENTAL
Intervention: Occurrence of VT/VF
Number of subjects: 13609
Study 36632831 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HFmrEF
Number of subjects: 13609
Study 36632983 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide (14 mg adult equivalent)
Number of subjects: 0
Study 36632983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36633115 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PSP/IPP-block before surgery
Number of subjects: 185
Study 36633115 — intervention group
Group type: COMPARATOR
Intervention: Long-acting opioids (intravenous morphine 30 min before emergence from anaesthesia)
Number of subjects: 185
Study 36633418 — intervention group
Group type: EXPERIMENTAL
Intervention: Operatively managed patients with ASH
Number of subjects: 218
Study 36633418 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SSI
Number of subjects: 218
Study 36633418 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Bluebelle scores
Number of subjects: 218
Study 36633470 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 352
Study 36633505 — intervention group
Group type: EXPERIMENTAL
Intervention: ADO09 (pramlintide/insulin A21G)
Number of subjects: 44
Study 36633505 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart
Number of subjects: 44
Study 36633570 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.6 mg/dose carbetocin
Number of subjects: 130
Study 36633570 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.2 mg/dose carbetocin
Number of subjects: 130
Study 36633570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 36633650 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront surgery
Number of subjects: 119
Study 36633650 — intervention group
Group type: COMPARATOR
Intervention: Active surveillance (AS)
Number of subjects: 119
Study 36633650 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy done outside of the center
Number of subjects: 119
Study 36633657 — intervention group
Group type: COMPARATOR
Intervention: LSHD group (n=42)
Number of subjects: 190
Study 36633816 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat 10 mg once daily (up-titrated from 2.5 mg to 5 mg to 10 mg at 14-day intervals)
Number of subjects: 74
Study 36633816 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (single dose on day 8 or day 50)
Number of subjects: 74
Study 36633816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 36633838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg twice daily for 10 days)
Number of subjects: 1288
Study 36633838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1288
Study 36633838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 1288
Study 36633844 — intervention group
Group type: EXPERIMENTAL
Intervention: ML recommender
Number of subjects: 1487
Study 36633844 — intervention group
Group type: COMPARATOR
Intervention: Standard messaging
Number of subjects: 1487
Study 36633844 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral tool kit
Number of subjects: 1487
Study 36633844 — intervention group
Group type: COMPARATOR
Intervention: No viral tool kit
Number of subjects: 1487
Study 36633848 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 159
Study 36633848 — intervention group
Group type: COMPARATOR
Intervention: Omnivorous diet
Number of subjects: 159
Study 36633848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 1 (before COVID-19)
Number of subjects: 159
Study 36633848 — intervention group
Group type: COMPARATOR
Intervention: Cohort 2 (during COVID-19)
Number of subjects: 159
Study 36633868 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral nudges to clinicians including weekly emails comparing SIC rates, weekly lists of high-risk patients, and opt-out text messages to prompt SICs before encounters.
Number of subjects: 20506
Study 36633868 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral nudges to clinicians
Number of subjects: 20506
Study 36633868 — intervention group
Group type: COMPARATOR
Intervention: Control group (no behavioral nudges)
Number of subjects: 20506
Study 36633877 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI guidance
Number of subjects: 156
Study 36633877 — intervention group
Group type: COMPARATOR
Intervention: CT guidance
Number of subjects: 156
Study 36633893 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time mobile intervention to reduce sedentary behavior (SB)
Number of subjects: 26
Study 36633893 — intervention group
Group type: COMPARATOR
Intervention: Monitoring-only control condition
Number of subjects: 26
Study 36633982 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined go/no-go and continuous performance task (GNG/CPT)
Number of subjects: 452
Study 36634022 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-ED intervention
Number of subjects: 690
Study 36634037 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based HIV risk reduction intervention
Number of subjects: 20
Study 36634369 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Endothelial Function (CEF) assessed by noninvasive MRI measures during isometric handgrip exercise
Number of subjects: 82
Study 36634369 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Endothelial Function (CEF) at baseline
Number of subjects: 82
Study 36634369 — intervention group
Group type: COMPARATOR
Intervention: Coronary Endothelial Function (CEF) after 8 weeks in the placebo group (N = 40)
Number of subjects: 82
Study 36634369 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic Endothelial Function (SEF) at baseline or 8 weeks
Number of subjects: 82
Study 36634369 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Endothelial Function (CEF) at 8 weeks
Number of subjects: 82
Study 36634389 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus bevacizumab
Number of subjects: 292
Study 36634389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 36634453 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 20
Study 36634453 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 20
Study 36634636 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation program (15 sessions)
Number of subjects: 30
Study 36634692 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV resurgence in summer and autumn 2021
Number of subjects: 310423
Study 36634920 — intervention group
Group type: EXPERIMENTAL
Intervention: Pixatimod 25 mg plus nivolumab 240 mg
Number of subjects: 58
Study 36635100 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational asbestos exposure
Number of subjects: 494
Study 36635100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever smoking
Number of subjects: 494
Study 36635100 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of ever smoking with occupational asbestos exposure
Number of subjects: 494
Study 36635100 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratification for genotype
Number of subjects: 494
Study 36635259 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV014
Number of subjects: 0
Study 36635304 — intervention group
Group type: EXPERIMENTAL
Intervention: β2-agonist treatment
Number of subjects: 0
Study 36635304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36635381 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept
Number of subjects: 68
Study 36635466 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-pore polypropylene mesh (Ultrapro)
Number of subjects: 181
Study 36635466 — intervention group
Group type: COMPARATOR
Intervention: Small-pore mesh
Number of subjects: 181
Study 36635514 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 47
Study 36635607 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis (ICA)
Number of subjects: 975
Study 36635607 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal anastomosis (ECA)
Number of subjects: 975
Study 36635633 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic decompensated heart failure
Number of subjects: 0
Study 36635633 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in dyspnea, MLHFQ, and TFI scores
Number of subjects: 0
Study 36635633 — intervention group
Group type: COMPARATOR
Intervention: Consultation frequency
Number of subjects: 0
Study 36635660 — intervention group
Group type: EXPERIMENTAL
Intervention: Durable Wall Lining (DWL) with non-pyrethroid insecticides
Number of subjects: 100
Study 36635660 — intervention group
Group type: COMPARATOR
Intervention: LLIN (Control)
Number of subjects: 100
Study 36635660 — intervention group
Group type: EXPERIMENTAL
Intervention: DWL
Number of subjects: 100
Study 36635679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation (iTBS) followed by video game-based training (VBT)
Number of subjects: 9
Study 36635679 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation followed by video game-based training (VBT)
Number of subjects: 9
Study 36635680 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported overweight and obesity at age 20
Number of subjects: 57902
Study 36635680 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain from age 20
Number of subjects: 57902
Study 36635690 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma GAS6 levels
Number of subjects: 1039
Study 36635690 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma GAS6 levels
Number of subjects: 1039
Study 36635690 — intervention group
Group type: EXPERIMENTAL
Intervention: GAS6 measurement
Number of subjects: 1039
Study 36635717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPET)
Number of subjects: 60
Study 36635717 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest computed tomography (CT) scan
Number of subjects: 60
Study 36635717 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak V'O
Number of subjects: 60
Study 36635741 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT-I intervention
Number of subjects: 180
Study 36635741 — intervention group
Group type: COMPARATOR
Intervention: Internet sleep education control
Number of subjects: 180
Study 36635741 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT-Pain intervention
Number of subjects: 180
Study 36635747 — intervention group
Group type: EXPERIMENTAL
Intervention: ERVIN.2 supported care
Number of subjects: 0
Study 36635747 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 36635747 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-utility analysis using EQ-5D-3L
Number of subjects: 0
Study 36635764 — intervention group
Group type: EXPERIMENTAL
Intervention: Root canal treatment in a single visit (RCT-SV)
Number of subjects: 150
Study 36635764 — intervention group
Group type: EXPERIMENTAL
Intervention: Root canal treatment in two visits with intracanal dressing (RCT-TVWD)
Number of subjects: 150
Study 36635764 — intervention group
Group type: EXPERIMENTAL
Intervention: Root canal treatment in two visits without intracanal dressing (RCT-TVWOD)
Number of subjects: 150
Study 36635764 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 150
Study 36635767 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib and letrozole
Number of subjects: 221
Study 36635767 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib and fulvestrant
Number of subjects: 221
Study 36635775 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation intervention (4-week duration, 4 facilitator-led group sessions, one per week)
Number of subjects: 71
Study 36635775 — intervention group
Group type: COMPARATOR
Intervention: Expressive writing control group
Number of subjects: 71
Study 36636059 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 22
Study 36636059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 36636112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (preterm birth prevention education, employment navigation toolkit, encouragement text messages)
Number of subjects: 30
Study 36636112 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 30
Study 36636112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 30
Study 36636296 — intervention group
Group type: EXPERIMENTAL
Intervention: Single, moderate dose of psilocybin (0.215 mg/kg body weight)
Number of subjects: 52
Study 36636296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 36636739 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 μg, subcutaneous)
Number of subjects: 30
Study 36636739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 36636751 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorized exercise using FitMi (computer game with 2 puck-like sensors, 3 hours/week for 3 weeks)
Number of subjects: 27
Study 36636751 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy using a paper book of exercises (3 hours/week for 3 weeks)
Number of subjects: 27
Study 36636767 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AEX) for 20 minutes at moderately-high intensity
Number of subjects: 30
Study 36636767 — intervention group
Group type: COMPARATOR
Intervention: Rest (non-exercise group)
Number of subjects: 30
Study 36636993 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 0
Study 36636993 — intervention group
Group type: COMPARATOR
Intervention: Emicizumab administration
Number of subjects: 0
Study 36636993 — intervention group
Group type: COMPARATOR
Intervention: Laboratory monitoring
Number of subjects: 0
Study 36636993 — intervention group
Group type: COMPARATOR
Intervention: Prophylaxis before minor surgery
Number of subjects: 0
Study 36636993 — intervention group
Group type: EXPERIMENTAL
Intervention: Major surgeries with emicizumab
Number of subjects: 0
Study 36637054 — intervention group
Group type: COMPARATOR
Intervention: HbF inducers (HQK-1001, Radix Astragali, CNP)
Number of subjects: 291
Study 36637054 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea versus resveratrol
Number of subjects: 291
Study 36637054 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea 20 mg/kg/day versus 10 mg/kg/day
Number of subjects: 291
Study 36637054 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea plus resveratrol versus resveratrol or hydroxyurea alone
Number of subjects: 291
Study 36637054 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea plus l-carnitine versus hydroxyurea alone
Number of subjects: 291
Study 36637138 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education (PNE)
Number of subjects: 184
Study 36637138 — intervention group
Group type: COMPARATOR
Intervention: Biomedical education
Number of subjects: 184
Study 36637153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg, 10 mg, 5 mg, 2.5 mg, 1 mg)
Number of subjects: 83
Study 36637153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (low-dose: 2.5-5 mg)
Number of subjects: 83
Study 36637153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (high-dose: 10-20 mg)
Number of subjects: 83
Study 36637153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 36637209 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (∼0.3 mg/kg) for 6 months
Number of subjects: 35
Study 36637209 — intervention group
Group type: COMPARATOR
Intervention: Placebo/control for 6 months
Number of subjects: 35
Study 36637540 — intervention group
Group type: EXPERIMENTAL
Intervention: Drip feeding (3-h continuous)
Number of subjects: 51
Study 36637540 — intervention group
Group type: COMPARATOR
Intervention: Intermittent feeding (bolus in 10 min)
Number of subjects: 51
Study 36637713 — intervention group
Group type: COMPARATOR
Intervention: LuCa course only
Number of subjects: 91
Study 36637713 — intervention group
Group type: EXPERIMENTAL
Intervention: LuCa + HD courses
Number of subjects: 91
Study 36637808 — intervention group
Group type: EXPERIMENTAL
Intervention: Myomectomy
Number of subjects: 0
Study 36637808 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine Artery Embolization
Number of subjects: 0
Study 36637994 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HbA1c
Number of subjects: 0
Study 36637994 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean HbA1c
Number of subjects: 0
Study 36637994 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c SD
Number of subjects: 0
Study 36637994 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-varying HbA1c
Number of subjects: 0
Study 36638072 — intervention group
Group type: EXPERIMENTAL
Intervention: Total artificial sweetener intake
Number of subjects: 103388
Study 36638072 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame intake
Number of subjects: 103388
Study 36638072 — intervention group
Group type: EXPERIMENTAL
Intervention: Acesulfame potassium intake
Number of subjects: 103388
Study 36638072 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose intake
Number of subjects: 103388
Study 36638112 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 300
Study 36638112 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 300
Study 36638112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 36638206 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-managed, music-guided exercise intervention
Number of subjects: 26
Study 36638206 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 26
Study 36638337 — intervention group
Group type: EXPERIMENTAL
Intervention: D+ RBC transfusion
Number of subjects: 42
Study 36638337 — intervention group
Group type: COMPARATOR
Intervention: Retrospective study of serologic D- pregnant women
Number of subjects: 42
Study 36638337 — intervention group
Group type: COMPARATOR
Intervention: Retrospective examination of serologic D- pregnant women with alloanti-D
Number of subjects: 42
Study 36638337 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of RHD transcripts from Asian-type DEL erythroblasts
Number of subjects: 42
Study 36638598 — intervention group
Group type: EXPERIMENTAL
Intervention: Active iTBS for 4 weeks
Number of subjects: 49
Study 36638598 — intervention group
Group type: COMPARATOR
Intervention: Sham iTBS for 4 weeks
Number of subjects: 49
Study 36638745 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical cannabis card (MCC)
Number of subjects: 181
Study 36638745 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 181
Study 36638819 — intervention group
Group type: EXPERIMENTAL
Intervention: SIIPL-PCV
Number of subjects: 660
Study 36638819 — intervention group
Group type: COMPARATOR
Intervention: PHiD-CV
Number of subjects: 660
Study 36638819 — intervention group
Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 660
Study 36638819 — intervention group
Group type: COMPARATOR
Intervention: SIIPL-PCV vs PHiD-CV
Number of subjects: 660
Study 36638819 — intervention group
Group type: COMPARATOR
Intervention: SIIPL-PCV vs PCV13
Number of subjects: 660
Study 36638837 — intervention group
Group type: EXPERIMENTAL
Intervention: CSCC_ASC injections
Number of subjects: 81
Study 36638837 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 81
Study 36639035 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA-PET/CT-guided intensification of radiation therapy (PSMAgRT)
Number of subjects: 253
Study 36639035 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 253
Study 36639130 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 13026
Study 36639130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13026
Study 36639200 — intervention group
Group type: EXPERIMENTAL
Intervention: FGFR3 inhibitor
Number of subjects: 0
Study 36639210 — intervention group
Group type: EXPERIMENTAL
Intervention: Video laryngoscope
Number of subjects: 0
Study 36639210 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscope
Number of subjects: 0